EA037067B1 - Селективные ингибиторы jak1 - Google Patents

Селективные ингибиторы jak1 Download PDF

Info

Publication number
EA037067B1
EA037067B1 EA201991700A EA201991700A EA037067B1 EA 037067 B1 EA037067 B1 EA 037067B1 EA 201991700 A EA201991700 A EA 201991700A EA 201991700 A EA201991700 A EA 201991700A EA 037067 B1 EA037067 B1 EA 037067B1
Authority
EA
Eurasian Patent Office
Prior art keywords
fluoro
methylsulfonyl
phenyl
indol
amino
Prior art date
Application number
EA201991700A
Other languages
English (en)
Russian (ru)
Other versions
EA201991700A1 (ru
Inventor
Карл Магнус Нильссон
Анника Биргитта Маргарета Остранд
Анна Ингрид Кристина Берггрен
Йохан Р. Йоханссон
Матти Юхани Лепистё
Самир Пралхад Каваткар
Цибинь Су
Джейсон Грант Кеттл
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of EA201991700A1 publication Critical patent/EA201991700A1/ru
Publication of EA037067B1 publication Critical patent/EA037067B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EA201991700A 2017-01-17 2018-01-16 Селективные ингибиторы jak1 EA037067B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762447057P 2017-01-17 2017-01-17
PCT/EP2018/051038 WO2018134213A1 (en) 2017-01-17 2018-01-16 Jak1 selective inhibitors

Publications (2)

Publication Number Publication Date
EA201991700A1 EA201991700A1 (ru) 2020-01-28
EA037067B1 true EA037067B1 (ru) 2021-02-02

Family

ID=61024756

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991700A EA037067B1 (ru) 2017-01-17 2018-01-16 Селективные ингибиторы jak1

Country Status (39)

Country Link
US (3) US10961228B2 (enExample)
EP (2) EP3571192B1 (enExample)
JP (3) JP6986086B2 (enExample)
KR (2) KR102585048B1 (enExample)
CN (2) CN110461830B (enExample)
AR (1) AR110753A1 (enExample)
AU (1) AU2018209667B2 (enExample)
CA (1) CA3049175A1 (enExample)
CL (1) CL2019001993A1 (enExample)
CO (1) CO2019007888A2 (enExample)
CR (1) CR20190332A (enExample)
DK (1) DK3571192T3 (enExample)
DO (1) DOP2019000184A (enExample)
EA (1) EA037067B1 (enExample)
EC (1) ECSP19051352A (enExample)
ES (1) ES2938648T3 (enExample)
FI (1) FI3571192T3 (enExample)
HR (1) HRP20230069T1 (enExample)
HU (1) HUE061064T2 (enExample)
IL (1) IL267851B (enExample)
JO (1) JOP20190174B1 (enExample)
LT (1) LT3571192T (enExample)
MA (1) MA47301B1 (enExample)
MX (2) MX390625B (enExample)
MY (1) MY199735A (enExample)
NI (1) NI201900077A (enExample)
NZ (1) NZ756069A (enExample)
PE (1) PE20191108A1 (enExample)
PH (1) PH12019501639B1 (enExample)
PL (1) PL3571192T3 (enExample)
PT (1) PT3571192T (enExample)
RS (1) RS63981B1 (enExample)
SG (1) SG11201906222WA (enExample)
SI (1) SI3571192T1 (enExample)
SM (1) SMT202300051T1 (enExample)
TW (1) TWI753089B (enExample)
UA (1) UA124246C2 (enExample)
WO (1) WO2018134213A1 (enExample)
ZA (1) ZA201906875B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20230069T1 (hr) * 2017-01-17 2023-03-17 Astrazeneca Ab Selektivni inhibitori jak1
PT3514153T (pt) 2017-01-26 2021-09-22 Hanmi Pharm Ind Co Ltd Composto de pirimidina e utilização farmacêutica do mesmo
EP3823964A1 (en) * 2018-07-18 2021-05-26 Astrazeneca AB A xinafoate salt of a jak inhibiting compound
KR101954370B1 (ko) 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
CN112823159B (zh) * 2018-09-21 2024-03-01 上海轶诺药业有限公司 一类具有激酶抑制活性的芳香杂环类化合物
PE20212153A1 (es) 2019-02-22 2021-11-09 Hanmi Pharm Ind Co Ltd Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda
CA3134174A1 (en) * 2019-04-19 2020-10-22 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Jak1 selective kinase inhibitor
KR20210002015A (ko) 2019-06-27 2021-01-06 한미약품 주식회사 Flt3 저해제 및 화학치료제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물
EP4132920B1 (en) * 2020-04-09 2025-08-13 Disarm Therapeutics, Inc. Indazole derivatives as inhibitors of sarm1
WO2022111499A1 (zh) * 2020-11-26 2022-06-02 深圳铂立健医药有限公司 一种酰胺化合物、药物组合物及其应用
JP2024509795A (ja) * 2021-02-26 2024-03-05 タイラ・バイオサイエンシーズ・インコーポレイテッド アミノピリミジン化合物及びその使用方法
US12240836B2 (en) * 2022-07-05 2025-03-04 Dong-A St Co., Ltd. Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof
CN115260128B (zh) * 2022-09-21 2022-12-09 苏州凯瑞医药科技有限公司 一种新型jak抑制剂关键中间体的制备方法
EP4648776A1 (en) * 2023-01-11 2025-11-19 Pfizer Inc. Compositions and methods for the treatment and/or prevention of type 1 diabetes
CN115974845B (zh) * 2023-01-19 2024-09-20 奥锐特药业股份有限公司 奥希替尼中间体的制备方法
TW202438061A (zh) * 2023-03-16 2024-10-01 美商英塞特公司 用於治療氣喘之jak1路徑抑制劑
GB202316063D0 (en) 2023-10-20 2023-12-06 Astrazeneca Ab Dosing regime
GB202403369D0 (en) 2024-03-08 2024-04-24 Astrazeneca Ab Process and intermediates for the production of a jak1 inhibitor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009046416A1 (en) * 2007-10-05 2009-04-09 Targegen Inc. Anilinopyrimidines as jak kinase inhibitors
WO2009118567A2 (en) * 2008-03-26 2009-10-01 The University Of Nottingham Pyrimidines, triazines and their use as pharmaceutical agents
WO2017050938A1 (en) * 2015-09-25 2017-03-30 Astrazeneca Ab Compounds and methods for inhibiting jak

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007004488A (es) * 2004-10-13 2007-09-11 Wyeth Corp Analogos de anilino-pirimidina n-bencenosulfonilo sustituidos.
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
CN101421250A (zh) * 2006-01-30 2009-04-29 埃克塞里艾克西斯公司 作为jak-2调节剂的4-芳基-2-氨基-嘧啶或4-芳基-2-氨基烷基-嘧啶及包含它们的药物组合物
JP2010518025A (ja) 2007-02-05 2010-05-27 アミラ ファーマシューティカルス,インコーポレーテッド 5−リポキシゲナーゼ活性化タンパク質(flap)インヒビターとしての逆インドール
WO2009045700A2 (en) 2007-10-05 2009-04-09 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
UA110324C2 (en) * 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
PH12015502575A1 (en) 2010-03-10 2017-04-24 Incyte Corp Piperidin-4-yl azetidine derivatives as jak1 inhibitors
JP5822934B2 (ja) * 2010-09-15 2015-11-25 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft アザベンゾチアゾール化合物、組成物及び使用方法
EP3060234A1 (en) 2013-10-24 2016-08-31 AbbVie Inc. Jak1 selective inhibitor and uses thereof
HRP20230069T1 (hr) * 2017-01-17 2023-03-17 Astrazeneca Ab Selektivni inhibitori jak1

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009046416A1 (en) * 2007-10-05 2009-04-09 Targegen Inc. Anilinopyrimidines as jak kinase inhibitors
WO2009118567A2 (en) * 2008-03-26 2009-10-01 The University Of Nottingham Pyrimidines, triazines and their use as pharmaceutical agents
WO2017050938A1 (en) * 2015-09-25 2017-03-30 Astrazeneca Ab Compounds and methods for inhibiting jak

Also Published As

Publication number Publication date
JP2024010041A (ja) 2024-01-23
CA3049175A1 (en) 2018-07-26
EP3571192A1 (en) 2019-11-27
HRP20230069T1 (hr) 2023-03-17
RS63981B1 (sr) 2023-03-31
EP3571192B1 (en) 2022-11-30
WO2018134213A1 (en) 2018-07-26
CN115925693B (zh) 2024-11-12
JP2020506171A (ja) 2020-02-27
CL2019001993A1 (es) 2019-12-27
CN115925693A (zh) 2023-04-07
ECSP19051352A (es) 2019-07-31
CN110461830A (zh) 2019-11-15
EP4219470A1 (en) 2023-08-02
IL267851B (en) 2021-08-31
JP7394820B2 (ja) 2023-12-08
PT3571192T (pt) 2023-02-21
JOP20190174B1 (ar) 2023-09-17
MX390625B (es) 2025-03-19
DK3571192T3 (da) 2023-02-06
ZA201906875B (en) 2021-05-26
MX2022002976A (es) 2022-04-06
SI3571192T1 (sl) 2023-03-31
MX2019008435A (es) 2019-09-09
KR20190104215A (ko) 2019-09-06
MA47301A (fr) 2019-11-27
PE20191108A1 (es) 2019-08-26
JP2022043059A (ja) 2022-03-15
FI3571192T3 (fi) 2023-03-06
MA47301B1 (fr) 2023-02-28
US10961228B2 (en) 2021-03-30
TW201838984A (zh) 2018-11-01
DOP2019000184A (es) 2019-08-15
NI201900077A (es) 2020-03-18
MY199735A (en) 2023-11-21
CO2019007888A2 (es) 2019-07-31
AU2018209667B2 (en) 2020-05-07
KR102659213B1 (ko) 2024-04-18
AU2018209667A1 (en) 2019-08-22
US20190367490A1 (en) 2019-12-05
BR112019014526A2 (pt) 2020-02-27
IL267851A (en) 2019-09-26
PH12019501639B1 (en) 2023-09-08
US12473272B2 (en) 2025-11-18
SMT202300051T1 (it) 2023-03-17
LT3571192T (lt) 2023-02-27
US20210188821A1 (en) 2021-06-24
JOP20190174A1 (ar) 2019-07-14
PH12019501639A1 (en) 2020-07-06
ES2938648T3 (es) 2023-04-13
KR20230141938A (ko) 2023-10-10
US20240208947A1 (en) 2024-06-27
NZ756069A (en) 2025-08-29
JP7626819B2 (ja) 2025-02-04
KR102585048B1 (ko) 2023-10-05
CN110461830B (zh) 2022-11-01
UA124246C2 (uk) 2021-08-11
US11897869B2 (en) 2024-02-13
AR110753A1 (es) 2019-05-02
JP6986086B2 (ja) 2021-12-22
PL3571192T3 (pl) 2023-03-20
TWI753089B (zh) 2022-01-21
CR20190332A (es) 2019-09-13
HUE061064T2 (hu) 2023-05-28
SG11201906222WA (en) 2019-08-27
EA201991700A1 (ru) 2020-01-28

Similar Documents

Publication Publication Date Title
JP7394820B2 (ja) Jak1選択的阻害剤
JP2023106425A (ja) アミノ酸化合物および使用方法
DK3207043T3 (en) DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR GAMMA
KR20230049584A (ko) 아미노산 화합물을 사용한 호흡기 질환의 치료
JP2024527623A (ja) 癌の治療のためのhpk1阻害剤としての置換ピラジン-2-カルボキサミド阻害剤
HK40098388A (en) Jak1 selective inhibitors
HK40017725B (en) Jak1 selective inhibitors
HK40017725A (en) Jak1 selective inhibitors
BR112019014526B1 (pt) Composto, composição farmacêutica e uso de um composto no tratamento de uma disfunção relacionada com jak1
HK40016478A (en) Jak1 selective inhibitors
HK40016478B (en) Jak1 selective inhibitors
HK1243402B (en) Dihydropyrrolopyridine inhibitors of ror-gamma
HK1243402A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma